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The aim of this work was to design a controlled-release drug-delivery system for the
angiotensin-II receptor antagonist drug telmisartan. Telmisartan was encapsulated with
different EUDRAGIT polymers by an emulsion solvent evaporation technique and the
physicochemical properties of the formulations were characterized. Using a solvent
evaporation method, white spherical microspheres with particle sizes of 629.9e792.1 mm
were produced. The in vitro drug release was studied in three different pH media (pH 1.2
for 2 hours, pH 6.8 for 4 hours, and pH 7.4 for 18 hours). The formulations were then
evaluated for their pharmacokinetic parameters. The entrapment efficiency of these
microspheres was between 58.6% and 90.56%. The obtained microspheres showed good
flow properties, which were evaluated in terms of angle of repose (15.29e26.32), bulk
and tapped densities (0.37e0.53 and 0.43e0.64, respectively), Carr indices and Hausner
ratio (12.94e19.14% and 1.14e1.23, respectively). No drug release was observed in the
simulated gastric medium up to 2 hours; however, a change in pH from 1.2 to 6.8
increased the drug release. At pH 7.4, formulations with EUDRAGIT RS 100 showed a
steady drug release. The microsphere formulation TMRS-3 (i.e., microspheres containing
2-mg telmisartan) gave the highest Cmax value (6.8641 mg/mL) at 6 hours, which was
three times higher than Cmax for telmisartan oral suspension (TOS). Correspondingly,
the area under the curve for TMRS-3 was 8.5 times higher than TOS. Particle size and
drug release depended on the nature and content of polymer used. The drug release
mechanism of the TMRS-3 formulation can be explained using the Higuchi model. The
controlled release of drug from TMRS-3 also provides for higher plasma drug content
and improved bioavailability.
Copyright © 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license. maceutics, I.T.S. Paramedical College (Pharmacy), Muradnagar, Ghaziabad, Uttar Pradesh
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The maintenance of drug content at the site of action is the
primary concern with any formulation design. Some con-
ventional dosage forms can provide poor management of
plasma drug concentrations. Drug-level fluctuations due to
frequent administration and variations in their absorption
and/or metabolism can result in toxic effects or render the
drugs ineffective [1,2]. These problems can be resolved by
designing new drug-delivery systems that can provide steady-
state plasma concentrations of the drug(s) administered.
Recently, extensive efforts have been dedicated to developing
controlled-release drug-delivery systems. Another advantage
of controlled-release drug delivery is enhancement of com-
mercial value of the product by increasing its patent life.
These dosage forms are designed to release the drug
constantly over an extended period [1].
Controlled drug delivery by encapsulating the drug inside
polymeric carriers has made great progress in last two de-
cades as it can enhance the drug release and decrease adverse
effects [3e6] by drug localization at the site of action and by
controlling the drug release [7]. Moreover, entrapment inside
the polymers can also shield the sensitive drugs (e.g., pep-
tides/proteins) from chemical and enzymatic decomposition.
Microspheres developed using biodegradable polymers are
widely used to achieve controlled release of drugs [8,9]. The
chief advantage of using biodegradable polymers is that after
performing their tasks they break down in a biologically
friendly manner.
Several microencapsulation techniques have been devel-
oped for this purpose; however, the appropriateness of such
techniques depends on the nature of the drug/polymer. The
most suitable microencapsulation techniques are emulsion
solvent evaporation, phase separation, interfacial polymeri-
zation, and spray drying. Of these methods, emulsion solvent
evaporation is themethod of choice formicroencapsulation of
water-insoluble drugs using a water-insoluble polymer
[4,10,11].
Telmisartan is a nonpeptide angiotensin-II receptor (type
AT1) antagonist. It blocks the vasoconstrictor and
aldosterone-secreting effects of angiotensin-II by selectively
blocking its binding to the AT1 receptor in adrenal gland and
smooth muscles of vasculature. Following oral administra-
tion, peak concentrations (Cmax) of telmisartan are achieved in
the 1st hour. The bioavailability of orally administered telmi-
sartan is nonlinear (20e160 mg) [12,13].
The rationale behind this study was to prepare the micro-
spheres of telmisartan encapsulated in EUDRAGIT polymers
to control the release of this highly base-soluble drug.
EUDRAGIT RS 100 and EUDRAGIT RL 100 are water-insoluble,
pH-independent polymers, whereas EUDRAGIT S 100 is a
pH-dependent polymer [14]. In addition, the drug-release ki-
netics for the formulations developed were also evaluated.2. Materials and methods
Telmisartan was obtained for IPCA (Ratlam, Madhya Pradesh,
India). The polymers EUDRAGIT RS 100, EUDRAGIT RL 100, andEUDRAGIT S 100were obtained fromEvonikDegussa India Pvt.
Ltd. (Saki Naka, Mumbai, India). Sodium lauryl sulfate (SLS),
disodium hydrogen phosphate, potassium dihydrogen phos-
phate, and polyvinyl alcohol (PVA) were obtained from CDH
(New Delhi, India). Analytical grade chloroform, sodium hy-
droxide, methanol, hydrochloric acid, and sodium chloride
were procured from Merck Ltd. (Mumbai, India)2.1. Preparation of microspheres (emulsion solvent
evaporation method)
Suitable amounts of polymer were added to a chloroform so-
lution of the drug. The aqueous phase was prepared by
dispersing 0.2% PVA (polyvinyl alcohol) in water. The
drugepolymer solution was added to the aqueous phase with
constant mixing. The mixture was stirred with a propeller at
500 rpm for 3 hours at 25C for complete removal of chloro-
form. The mixture was filtered to collect the microspheres,
which were then washed with deionized water (Fig. 1). These
microspheres were dried at room temperature for 24 hours
[14e18]. The compositions of the different formulations are
shown in Table 1 and the steps involved in their production
are illustrated in Fig. 1.2.2. Characterization
2.2.1. Drug entrapment efficiency, drug loading, and drug
yield
Microspheres (25 mg) were dissolved in 25 mL methanol and
the resulting solutionwas filtered. The filtrate was diluted and
analyzed for drug content [19,20] using the following
equations:
Entrapment efficiency

%
 ¼ Actual loading
Theoretical loading
 100 (1)
Drug loading

%
 ¼ Weight of drug in microspheres
Weight of microsphere
 100
(2)
Yield

%
 ¼ Weight of microsphere
Total expectedweight of drug andpolymer
 100
(3)
Drug loading, percentage yield, and the drug encapsulation
efficiency for all batches are presented in Table 1.
2.2.2. Micromeritic studies of microspheres
Micromeritic studies of microspheres were performed as
described earlier [21].
2.2.2.1. Angle of repose. The fixed funnelmethodwas used for
estimating the angle of repose for different formulations [11],
(n ¼ 3).
q ¼ tan1hr (4)
where q is angle of repose, r is the radius, and h is the height.
2.2.2.2. Bulk density and tapped density. Microspheres (5 g)
were added into a 5-mL graduated cylinder and the final
Table 1 e Percentage yield, percentage loading, and encapsulation efficiency of telmisartan microspheres.
S. no. Formulation
code
Drug:polymer
ratio
Theoretical
loading (%)
Actual drug
loading (%)
Encapsulation
efficiency (%)
Yield
(%)
1 TMS-1 1:1 50.00 29.3 ± 1.37 58.6 ± 0.42 76.3
2 TMS-2 1:2 33.33 21.50 ± 1.1 64.50 ± 1.3 74.8
3 TMS-3 1:3 25.00 18.49 ± 1.2 73.96 ± 1.5 80.3
4 TMRL-1 1:1 50.00 29.48 ± 0.83 58.96 ± 1.61 68.7
5 TMRL-2 1:2 33.33 20.37 ± 1.22 61.11 ± 0.33 84.9
6 TMRL-3 1:3 25.00 17.64 ± 1.3 70.56 ± 0.81 77.5
7 TMRS-1 1:1 50.00 33.26 ± 1.82 66.52 ± 1.03 81.4
8 TMRS-2 1:2 33.33 25.43 ± 1.52 76.29 ± 0.53 87.3
9 TMRS-3 1:3 25.00 22.64 ± 0.96 90.56 ± 0.26 92.5
All data are expressed as mean ± standard deviation; n ¼ 3.
TMRL ¼ telmisartan þ EUDRAGIT RL 100; TMRS ¼ telmisartan þ EUDRAGIT RS 100; TMS ¼ telmisartan þ EUDRAGIT S 100.
Fig. 1 e Production of microspheres by the emulsion solvent evaporation technique.
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Fig. 2 e Scanning electronmicroscopy image of the TMRS-3
formulation. SEI ¼ secondary electron imaging; TMRS-
3 ¼ microspheres containing 2-mg telmisartan.
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cylinder was then tapped mechanically 100 times to obtain
the tapped volume for computing the tapped density (Dt)
[16,22].
2.2.2.3. Carr's index. Carr index [23] and Hausner ratio [24]
were calculated using following equations:
Carr index ¼ ðDt  DbÞ  100=Dt (5)
Hausner ratio ¼ Dt=Db (6)
2.2.3. Particle-size analysis
The sizes of the microspheres were determined using an
optical microscope (Olympus, Tokyo, Japan) fitted with an
ocular micrometer. The ocular micrometer was calibrated
with a stage micrometer. A total of 100 microspheres were
evaluated and the mean diameter was reported. The average
particle size for each formulation (n ¼ 3) is presented in
Table 2.
2.2.4. Scanning electron microscopy
Scanning electronmicroscopy (SEM)was used for determining
the surface morphology (JEOL JSM 5800; JEOL, Tokyo, Japan).
The microspheres were fixed in slabs and coated with gold/
palladiumusing a sputter coater. The SEM image of the TMRS-
3 (i.e., microspheres containing 2-mg telmisartan) formula-
tion is shown in Fig. 2.
2.2.5. Determination of drug amount using high-performance
liquid chromatography assay
Drug content was determined by high-performance liquid
chromatography (HPLC) using an LC-10ATVP HPLC pump, an
SIL-10AF auto injector, an SPD-10A UV/Vis detector, and an
SCL-10A VP system controller (all from Shimadzu, Kyoto,
Japan). A Shim-pack VP-ODS (4.6 mm i.d.  150 mm) packed
with an adsorbent (5-mm; Shimadzu) was eluted with aceto-
nitrile/methanol (60:40, v/v) isocratically. The elution was
performed at 1.0 mL/minute using a sample volume of 20 mL.
The UV detector was set at 296 nm for detection [2]. A linear
correlation was achieved between drug content and peak area
at 2e40 ng/mL (drug concentration). The equation describing
the calibration curve for telmisartan was y ¼ 26,966x e 49,352Table 2 e Micromeritic properties of telmisartan microspheres
Formulation
code
Angle of
repose ()
Bulk density
(g/mL)
Tapped
(g
TMS-1 26.32 ± 0.49 0.52 ± 0.02 0.61
TMS-2 22.43 ± 0.91 0.53 ± 0.04 0.64
TMS-3 22.19 ± 0.93 0.46 ± 0.02 0.54
TMRL-1 19.45 ± 0.34 0.51 ± 0.01 0.60
TMRL-2 20.43 ± 0.84 0.37 ± 0.05 0.43
TMRL-3 23.89 ± 0.45 0.49 ± 0.03 0.57
TMRS-1 15.98 ± 0.93 0.43 ± 0.03 0.53
TMRS-2 18.39 ± 0.48 0.39 ± 0.06 0.45
TMRS-3 15.29 ± 0.89 0.53 ± 0.09 0.60
All data are expressed as mean ± standard deviation; n ¼ 3.
TMRL ¼ telmisartan þ EUDRAGIT RL 100; TMRS ¼ telmisartan þ EUDRAG(R2 ¼ 0.999), where x is the concentration and y is the peak
area.
2.2.6. In vitro dissolution study
The drug-release study was carried out in the USP dissolution
apparatus II using 100 mg of the formulation at 37 ± 0.5C. For
simulation of physiological conditions, the study was carried
out at three different pH conditions, namely, at pH 1.2 (simu-
latedgastricfluid)and6.8and7.4 (simulated intestinalfluid) [25].
Initially, the microspheres were treated with 900 mL of
0.1N (pH 1.2) hydrochloric acid containing 0.01% SLS for 2
hours [4]. After 2 hours, 25.92 g disodium hydrogen phosphate
and 10.305 g dihydrogen potassium phosphate were added to
increase the pH to 6.8 and the drug-release study was
continued for another 4 hours. After the 6 hours, 2.142 g
disodium hydrogen phosphate and 0.171 g sodium chloride
were again added in order to increase the pH up to 7.4 and the
studywas continued for up to 24 hours [19,22,26]. The samples
were withdrawn at suitable intervals and replaced with fresh
medium. The aliquots were suitably diluted and drug content
was determined by HPLC..
density
/mL)
Carr index Hausner
ratio
Particle
size (mm)
± 0.02 14.12 ± 0.21 1.17 ± 0.01 752.9 ± 4.9
± 0.02 18.18 ± 0.9 1.2 ± 0.03 769.3 ± 8.3
± 0.01 17.32 ± 0.8 1.2 ± 0.02 792.1 ± 6.3
± 0.03 15.13 ± 0.95 1.17 ± 0.05 702.4 ± 7.3
± 0.04 14.2 ± 1.3 1.16 ± 0.02 730.7 ± 4.8
± 0.02 15.1 ± 1.01 1.16 ± 0.03 757.3 ± 6.5
± 0.03 19.14 ± 1.03 1.23 ± 0.03 629.9 ± 7.3
± 0.04 15.15 ± 1.3 1.15 ± 0.02 653.3 ± 4.5
± 0.01 12.94 ± 1.1 1.14 ± 0.02 686.2 ± 5.8
IT RS 100; TMS ¼ telmisartan þ EUDRAGIT S 100.
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Fig. 3 e In vitro release profile of microspheres (TMS, TMRL,
and TMRS formulations) at different pH conditions (1e2
hours at pH 1.2; 3e6 hours at pH 6.8; and 7e24 hours at pH
7.4). TMRL ¼ telmisartan þ EUDRAGIT RL 100;
TMRS ¼ telmisartan þ EUDRAGIT RS 100;
TMS ¼ telmisartan þ EUDRAGIT S 100.
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The experimental protocol for in vivo drug permeation study
was prepared and approved by the Institutional Animal Ethics
Committee. Male albino rats (Wistar strain; average age, 6e8
weeks; average weight, 200 g) were housed in polypropylene
cages under standard laboratory conditions with free access
to food and water. The animals were divided into the
following three groups (telmisartan dose, 10 mg/kg):
Group I ¼ no treatment (control group)
Group II ¼ telmisartan oral suspension (TOS)
Group III ¼ TMRS-3 formulation
Suitable blood samples were removed at predetermined
time intervals and processed for plasma separation [27e30].
The drug content was determined by HPLC assay.
2.3. Release kinetics
Data obtained from in vitro release studies were fitted to
various kinetics equations (zero-order, first-order, and Higu-
chi models) to find out the mechanism of drug release from
microspheres. The rate constants were also calculated for the
respective models [31].
2.4. Data and statistical analysis
All data were presented asmean ± SD. Statistical analysis was
performed using the GraphPad Prism Version 4 software
(GraphPad Software, Inc., La Jolla, CA, USA). Analysis of vari-
ance or the paired t test was used as appropriate for statistical
analysis, and the statistical significance was set at p < 0.05.0
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Fig. 4 e Plasma drug concentration profiles of TOS and
TMRS-3. TMRS-3 ¼ microspheres containing 2-mg
telmisartan; TOS ¼ telmisartan oral suspension.3. Results
3.1. Micromeritic studies of microspheres
White, spherical, and free-flowing microspheres were pro-
duced using the solvent evaporation method. The percentage
yield varied from 68.7% to 92.5%, with the highest yield ob-
tained for TMRS-3. The results show that increase in polymer
ratio increases product yield.
It has been reported that higher molecular weight poly-
mers show better precipitation of polymer at the boundary
phase of the droplets owing to the increase of hydrophobicity
[32]. Mean particle size has been shown to increase with
increasing polymer concentration, which could be due to in-
crease in relative viscosities.
All the formulations were free flowing as indicated by the
angle of repose value less than 30. The values of bulk and
tapped densities have shown good packing ability. The values
of Carr indices were 12.94e19.14% with the lowest Ci value for
TMRS-3, indicating its excellent compressibility. The Hausner
ratio for the formulations was in the range of 1.14e1.23,
showing their good flow properties.
After considering various micromeritic parameters, it can
be inferred that TMRS-3 is the best formulation having the
best flow properties with low angle of repose value (15.29),
lowest Carr index (12.94%), and low Hausner ratio (1.14).3.2. Drug-release behavior
The drug-release behavior was studied up to 24 hours, simu-
lating the physiological conditions using simulated gastric
fluid (0.1N HCl, pH 1.2) and simulated intestinal fluid (pH 6.8
and 7.4). All the formulations showed negligible amounts of
drug in the simulated gastric fluid; however, a change in the
medium shows a difference in drug release. Further change in
pH from 6.8 to 7.4 results in constant drug release up to 24
hours (Fig. 3).
3.3. In vivo studies
TMRS-3 was selected based on the physicochemical parame-
ters and evaluated for in vivo permeation against TOS. The
Cmax for TMRS-3 was three times more than that of TOS when
Table 3 e Cmax, tmax, and AUC0/24 values for TOS and
TMRS-3 formulations.
Formulation
code
Cmax (mg/mL) tmax (h) AUC (mg h/mL)
TOS 2.305 ± 0.08 2 15.86 ± 0.98
TMRS-3 6.8641 ± 0.14 6 127.6 ± 1.73
All data are expressed as mean ± standard deviation; n ¼ 6;
(p  0.05).
AUC ¼ area under the curve; TMRS-3 ¼microspheres containing 2-
mg telmisartan; TOS ¼ telmisartan oral suspension (10 mg/kg).
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modified from 2 to 6 hours (Fig. 4). TMRS-3 had the highest
plasma drug content, which was reflected by its higher
bioavailability (TMRS-3 had 8.5 times more bioavailability
than TOS; Table 3).
3.4. Release kinetics
The drug-release mechanism was studied by comparing the
respective correlation coefficients for different releasemodels
(Table 4). It was observed that the drug release was diffusion
controlled in the TMRS formulation.4. Discussion
The microspheres were formulated using different grades of
EUDRAGIT polymers, which vary in molecular weight and the
resulting viscosities as well as in behavior at different pH
values. Based on these results, it can be inferred that as the
drug polymer ratio increases, product yield also increases.
The actual drug loading increased with an increase in
theoretical drug loading. It has been reported that as the
molecular weight of the polymer increases, its hydrophobicity
also increases, thereby leading to better precipitation of
polymer at the boundary phase of the droplets; however, the
molecular weights for EUDRAGIT RS 100 and RL 100 were the
same. The difference lies in their behavior when they come in
contact with water. EUDRAGIT RL 100 has more permeability
than EUDRAGIT RS 100.Table 4 e Release kinetic studies of telmisartan microspheres.
Formulation
code
Zero-order model Higuchi mode
R2 R2 KH (relea
const
TMS-1 0.9647 0.9621 33.2
TMS-2 0.967 0.9446 29.2
TMS-3 0.9522 0.9366 26.7
TMRL-1 0.9835 0.9863 29.8
TMRL-2 0.9615 0.9794 27.7
TMRL-3 0.8626 0.9356 19.8
TMRS-1 0.9098 0.9907 21.6
TMRS-2 0.919 0.9918 17.6
TMRS-3 0.9576 0.9953 15.1
TMRL ¼ telmisartan þ EUDRAGIT RL 100; TMRS ¼ telmisartan þ EUDRAGParticle-size distribution is affected by the interaction be-
tween the dispersed phase and the dispersionmedium. In our
study, the mean particle size increases with the increase in
polymer concentration due to increase in relative viscosity.
All the formulations have shown free-flowing nature with
good packability. The formulations having 1:1 drug-to-
polymer ratio demonstrated enhanced release properties.
The maximum drug release was for TMS-1
(telmisartan þ EUDRAGIT S 100), whereas the minimum
drug release was for TMRS-3. The drug release was decreased
with increase in polymer content. This could be explained
based on particle-size distribution. Increase in polymer con-
tent increases particle size, which subsequently decreases the
effective surface area. In addition, the path length traveled by
the drug molecule is also increased. The formulation con-
taining EUDRAGIT RS 100 showed the slowest drug release,
because it is the least permeable polymer due to the presence
of less quaternary groups than that in EUDRAGIT RL 100. By
contrast, EUDRAGIT S 100 dissolves at and above pH 7 as it is a
pH-dependent polymer. The study also shows the drug release
at pH 6.8 from EUDRAGIT S 100, which may be due to the pore
formation after swelling of the polymer.
The efficiency of the selected formulation (TMRS-3) was
evaluated in rats for in vivo parameters because an in vivo
study in humans is not a practical option. However, animal
studies can give a realistic assumption of drug content in the
living system. Controlled drug release from TMRS-3 can also
provide for maximal absorption of telmisartan in the tissues.
The release mechanism was studied by comparing the
values of correlation coefficients, and the drug release was
found to be controlled by diffusion of drug through the
microsphere matrix (TMRS formulation). The Higuchi model
was found to be the best fitted for drug release from telmi-
sartan microspheres of TMRS formulations.5. Conclusion
Telmisartan microspheres were formulated and evaluated for
drug release in simulated physiological conditions. The
selected formulation was evaluated in rats for in vivo drug
absorption. It was observed that the content of the polymer
manipulates the physical parameters along with the drug-l First-order model KorsmeyerePeppas
model
se rate
ant)
R2 n (release
exponent)
R2
84 0.93 1.6654 0.9351
38 0.8939 1.9404 0.9532
14 0.8588 1.102 0.9674
97 0.8364 1.0751 0.9217
14 0.9709 1.0273 0.9133
34 0.9877 0.7116 0.9505
54 0.9892 0.7159 0.8991
98 0.9849 0.6716 0.9481
03 0.9813 0.5605 0.9729
IT RS 100; TMS ¼ telmisartan þ EUDRAGIT S 100.
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microspheres with adequate encapsulation efficiency, with
the highest for TMRS-3. The particle size increased with in-
crease in polymer content.
The release kinetic study has shown that drug release from
telmisartan microspheres (TMRS formulations) follows the
Higuchi model as the drug release occurs by diffusion.
The formulations have shown good drug release in simu-
lated intestinal medium, which is the desired medium for
drug absorption. In addition, the release continues at a con-
stant rate in this medium.Conflicts of interest
All contributing authors declare no conflicts of interest.
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